New Mifcare PAH Therapy Shows Beneficial Results, According to Pre-Clinical Animal Test
Mifcare, a Paris-based biotechnology company recently announced positive pre-clinical results for their compound MFC1040.
Mifcare, a Paris-based biotechnology company recently announced positive pre-clinical results for their compound MFC1040.
Researchers from the U.S., Germany, Switzerland, and the U.K. have developed a new questionnaire, to help assess symptoms of pulmonary arterial hypertension (PAH) and the disease’s impact on patients’ lives. The questionnaire, called PAH-SYMPACT, was created following guidance from the U.S. Food and Drug Administration (FDA) to include patient reported outcomes…
Get regular updates to your inbox.